Arcadia Biosciences Raises $2.1M with Preferred Investment Option Exercise

Arcadia Biosciences has entered into definitive agreements to exercise preferred investment options, purchasing up to 808,595 shares at a reduced exercise price of $2.575 per share. The gross proceeds from the exercise are expected to be approximately $2.1 million. The shares are registered under effective registration statements on Form S-1 and Form S-3. H.C. Wainwright & Co. is acting as the placement agent.